Skip to main content
Premium Trial:

Request an Annual Quote

Cytokinetics Closes $20M Round of Financing, Adds New Board Members

Premium

SOUTH SAN FRANCISCO, Calif.--Cytokinetics, a privately held biotechnology and informatics company here that is developing a cellular bioinformatics database based on cytoskeletal pharmacology, announced that it has completed a $20 million Series B Preferred Stock financing round. Investors included International Biomedicine Holdings, Microsoft co-founder Paul Allen's Vulcan Ventures, Duke University, and New Medical Technologies, Mayfield Fund, and Sevin Rosen Funds. Along with the funding, the company has added William Rutter, founder and former chairman of Chiron, and Stefan Ryser, partner of International Biomedicine Management Partners, to its board of directors.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.